Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Content Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk already made me a "wealthy man"
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific types of cancer with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of meaningful sales. Two smaller biotech companies are enjoying strong share-price momentum thanks to their leading oncology medicines. Beyond the clinical promise, these drugs could help the firms progress toward greater stability and eventual profitability. That said, both remain high-risk investments: typical biotech ventures with the potential for outsized rewards but also substantial challenges. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle JPMorgan Chase just admitted to abruptly shutting down bank accounts affiliated with Donald Trump post regarding the events of Jan. 6, 2021—if a handful of banking executives can unilaterally lock a billionaire and ex-President out of the banking system over politics, what chance do you and I have? Buried in Federal Reserve Docket No. OP-1670 is the blueprint for FedNow, a centralized hub that gives the Fed real-time visibility into every payment you make and the power to flag or freeze your money with a single keystroke, and over 1,500 banks have already plugged into FedNow. See the 4 steps to Fed-proof your savings now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) gains, which have more than doubled so far. Still, with a consensus price target of $8.88, Wall Street is implying additional upside—about 71% from current levels. The primary catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and has gained momentum in sales, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and may be effective against other tumor types. Some of Iovance's outperformance this year is also tied to its Q4 2025 earnings report, issued in late February, in which the company reported a narrower-than-expected loss per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year (YOY). Iovance is still a relatively small biotech (about a $2 billion market cap) and remains a higher-risk investment. Analysts are cautious: roughly half of its ~12 analyst ratings are Hold or Sell. Beyond the usual risks for smaller biotech firms, Amtagvi's personalized, costly and complex manufacturing process could limit margins and slow the company's path to profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance still dwarfs Iovance's: IBRX shares are up nearly 300% in 2026. Analysts' consensus price target of $13.60 implies roughly 70% more upside from current levels. ImmunityBio's growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares spiked after the European regulator granted conditional marketing authorization, the latest in a string of approvals around the world. Anktiva is driving the firm's revenue: sales reached $113 million last year, roughly a 700% YOY increase. Like Amtagvi, Anktiva is being investigated for additional cancer indications, which could expand its market opportunity. However, IBRX remains speculative. The company posted a substantial net loss of $351 million for 2025 as R&D expenses continued to climb. Analysts are somewhat more bullish on ImmunityBio than on Iovance—six of seven coverage analysts rate the stock a Buy or equivalent—but significant execution and financial risks remain. Both companies illustrate the biotech trade-off: potentially transformative medicines that can drive rapid growth, paired with manufacturing, regulatory and financial challenges that can make outcomes uncertain. For investors, these names offer high upside alongside high risk, making thorough due diligence essential before allocating capital. | 
